Bristol Myers Squibb (BMY) reported $48.2B in revenue for fiscal 2025, −0.2% year on year. That ranks #110 by revenue among 2853 SEC filers and #17 in Healthcare. Net income was $7.1B, a net margin of 14.6%. Revenue has grown 10.6% a year on average since 2016 ($19.4B then). The fiscal 2025 balance sheet shows $90.0B in total assets, $10.2B in cash and $42.9B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $48.2B | −0.2% | FY20252025-12-31 |
| Gross profitGrossProfit | $30.7B | +70.2% | FY20202020-12-31 |
| Operating incomeIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | $9.3B | +$17.7B | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $7.1B | +$16.0B | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $14.2B | −6.8% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.3B | +5.0% | FY20252025-12-31 |
| Total assetsAssets | $90.0B | −2.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $18.5B | +13.1% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $10.2B | −1.3% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $42.9B | −10.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $11.5B | $2.7B | Open → |
| Q2 20262026-06-30 | $13.0B | $3.3B | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 40 of 161 companies compared | 14.6% | |
| Operating marginRank 38 of 160 companies compared | 19.4% | |
| R&D as share of revenueRank 23 of 102 companies compared | 20.6% | |
| Cash as share of revenueRank 48 of 160 companies compared | 21.2% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Bristol Myers Squibb Co
- Ticker
- BMY
- Exchange
- NYSE
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000014272
Filings
- 10-QJul 30, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 11, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| PfizerPFE | $62.6B | $7.8B |
| AbbVieABBV | $61.2B | $4.2B |
| AstraZenecaAZN | $58.7B | $10.2B |
| Bristol Myers SquibbBMY | $48.2B | $7.1B |
| Novo Nordisk A SNVO | $46.8B | $15.5B |
| Molina HealthcareMOH | $45.4B | $472M |
| Abbott LaboratoriesABT | $44.3B | $6.5B |
Bristol Myers Squibb compared withAstraZenecaNovo Nordisk A S
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Bristol Myers Squibb — Key figures |url=https://companiesranked.com/en/company/bristol-myers-squibb |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Bristol Myers Squibb — Key figures. CompaniesRanked. https://companiesranked.com/en/company/bristol-myers-squibbBibTeX
@misc{companiesranked-en-company-bristol-myers-squibb-2026,
author = {{CompaniesRanked}},
title = {{Bristol Myers Squibb — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/bristol-myers-squibb}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000014272-26-000004 · February 11, 2026
{{cite web |title=Bristol Myers Squibb — Key figures — 10-K (0000014272-26-000004) |url=https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.